Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today's Pharmaceutical Executive Daily, InnoCare Pharma enters a research collaboration and license agreement with Eli Lilly worth up to $3.35 billion to apply InnoCare's drug discovery platform against up to five undisclosed targets, FDA approves Eli Lilly's Onswik, a once-weekly basal insulin, for adults with type 2 diabetes, and Jen Lamppa argues that real-world data and AI can fix clinical trials' patient enrollment problem.
InnoCare Pharma has entered a research collaboration and license agreement with Eli Lilly and Company worth up to $3.35 billion, applying InnoCare's drug discovery platform against up to five undisclosed targets to address critical unmet medical needs. Under the deal, InnoCare stands to receive up to $100 million in upfront and near-term payments plus up to roughly $3.25 billion tied to milestones, along with tiered royalties on net sales. Jasmine Cui, InnoCare's co-founder, chairwoman, and chief executive officer, says the company is excited to leverage its R&D platform alongside a global pharmaceutical leader like Lilly.
FDA has approved Onswik, Eli Lilly's once-weekly basal insulin, for adults with type 2 diabetes alongside diet and exercise. The approval rests on the Phase III Qwint program, four global studies enrolling more than 3,400 adults, which found Onswik non-inferior on A1C reduction to daily basal insulins insulin glargine U-100 and insulin degludec U-100, with a comparable safety profile. Onswik is expected to become available in the coming months in two concentrations.
Finally, Jen Lamppa, senior vice president of commercial strategy, argues that clinical trial sponsors should stop relying on self-reported patient histories to screen enrollees, since patients often struggle to accurately recall their own medical records under time pressure, leading to costly audits, exclusions, and safety signals that can derail a study. Lamppa contends that pairing real-world data with AI-powered analysis of unstructured clinical notes and records can validate patient histories before enrollment even begins, an approach recent FDA guidance has begun to encourage.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
